Eli Lilly | LLY - 债务





债务 更改 日
AbbVie USD 67.5B 67.5B 2025-12
Abbott USD 13.86B 919M 2025-12
ALKERMES USD 1.58B 1.51B 2026-03
Amgen USD 54.6B 17M 2025-12
AstraZeneca USD 33.92B 4.3B 2026-03
Baxter International USD 9.78B 68M 2025-12
Biogen USD 6.56B 275.1M 2026-03
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Coherus Biosciences USD 294.92M 1.25M 2025-03
Drreddys Laboratories INR 67.73B 19.09B 2025-12
Eli Lilly USD 42.5B 3.6M 2025-12
Gilead Sciences USD 24.94B 5M 2025-12
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Glaxosmithkline GBP 17.75B 396M 2025-09
J&J USD 47.93B 2.14B 2025-12
Medtronic USD 28.07B 1.03B 2025-12
Merck USD 49.34B 7.97B 2025-12
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novartis USD 47B 11.62B 2026-03
Novartis USD 32.02B 615M 2025-09
Novo Nordisk DKK 118.72B 61.75B 2025-03
Perrigo USD 3.64B 4.5M 2025-12
Pfizer USD 63.73B 231M 2026-03
Phibro Animal Health USD 474.17M 730K 2024-09
Prestige Brands USD 1.08B 38.27M 2025-12
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Roche Holding CHF 33.03B 1.41B 2025-06
Sanofi EUR 20.33B 1.43B 2025-12
Sanofi EUR 21.76B 530M 2025-09
United Therapeutics USD 200M 100M 2025-03
Zoetis USD 9.24B 1.96B 2025-12